156 related articles for article (PubMed ID: 32338080)
1. Comparison of the effect of topical bevacizumab and sorafenib in experimental corneal neovascularization.
Yildirim H; Aydemir O; Balbaba M; Özercan İH; İlhan N
Cutan Ocul Toxicol; 2020 Sep; 39(3):223-228. PubMed ID: 32338080
[TBL] [Abstract][Full Text] [Related]
2. Effects of sunitinib and bevacizumab on VEGF and miRNA levels on corneal neovascularization.
Cakmak H; Gokmen E; Bozkurt G; Kocaturk T; Ergin K
Cutan Ocul Toxicol; 2018 Jun; 37(2):191-195. PubMed ID: 28874077
[TBL] [Abstract][Full Text] [Related]
3. Effect of topical motesanib in experimental corneal neovascularization model.
Çelenk M; Yıldırım H; Tektemur A; Balbaba M; Erdağ M
Int Ophthalmol; 2023 Aug; 43(8):2989-2997. PubMed ID: 36971928
[TBL] [Abstract][Full Text] [Related]
4. The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization.
Eski MT; Teberik K; Oltulu P; Ankaralı H; Kaya M; Alpay M
Hum Exp Toxicol; 2022; 41():9603271221084674. PubMed ID: 35465742
[TBL] [Abstract][Full Text] [Related]
5. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
[TBL] [Abstract][Full Text] [Related]
6. [Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model].
Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Fernández-Sánchez L; Cuenca-Navarro N
Arch Soc Esp Oftalmol; 2013 Dec; 88(12):473-81. PubMed ID: 24257257
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization.
Ozdemir O; Altintas O; Altintas L; Ozkan B; Akdag C; Yüksel N
Arq Bras Oftalmol; 2014 Aug; 77(4):209-13. PubMed ID: 25410169
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Effects of Dovitinib and Bevacizumab on Reducing Neovascularization in an Experimental Rat Corneal Neovascularization Model.
Sahan B; Ciftci F; Eyuboglu S; Yaba A; Yilmaz B; Yalvac BI
Cornea; 2019 Sep; 38(9):1161-1168. PubMed ID: 31180924
[TBL] [Abstract][Full Text] [Related]
9. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
[TBL] [Abstract][Full Text] [Related]
10. Effects of Combined Photodynamic Therapy and Topical Bevacizumab Treatment on Corneal Neovascularization in Rabbits.
Kim RY; Chung SK; Kim MS; Ra H
Cornea; 2016 Dec; 35(12):1615-1620. PubMed ID: 27684458
[TBL] [Abstract][Full Text] [Related]
11. Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization.
Ozdemir O; Altintas O; Altintas L; Yildiz DK; Sener E; Caglar Y
Can J Ophthalmol; 2013 Apr; 48(2):115-20. PubMed ID: 23561605
[TBL] [Abstract][Full Text] [Related]
12. The effect of bevacizumab on corneal neovascularization in rabbits.
Kim WJ; Jeong HO; Chung SK
Korean J Ophthalmol; 2010 Aug; 24(4):230-6. PubMed ID: 20714387
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model.
Sella R; Gal-Or O; Livny E; Dachbash M; Nisgav Y; Weinberger D; Livnat T; Bahar I
Exp Eye Res; 2016 May; 146():224-232. PubMed ID: 27020759
[TBL] [Abstract][Full Text] [Related]
14. Effect of bevacizumab on corneal neovascularization in experimental rabbit model.
Ahmed A; Berati H; Nalan A; Aylin S
Clin Exp Ophthalmol; 2009 Sep; 37(7):730-6. PubMed ID: 19788671
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
16. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization.
Habot-Wilner Z; Barequet IS; Ivanir Y; Moisseiev J; Rosner M
Acta Ophthalmol; 2010 Dec; 88(8):862-7. PubMed ID: 19549103
[TBL] [Abstract][Full Text] [Related]
17. Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization.
Kaya MK; Demir T; Bulut H; Akpolat N; Turgut B
Clin Exp Ophthalmol; 2015 Jul; 43(5):449-57. PubMed ID: 25640924
[TBL] [Abstract][Full Text] [Related]
18. The inhibitory effects of trastuzumab on corneal neovascularization.
Güler M; Yilmaz T; Ozercan I; Elkiran T
Am J Ophthalmol; 2009 Apr; 147(4):703-708.e2. PubMed ID: 19054498
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
[TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
